following a full submission assessed under the end of life process:
pembrolizumab (Keytruda) is not recommended for use within NHSScotland.
Indication under review: in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations.
The addition of pembrolizumab to pemetrexed and platinum chemotherapy significantly improved progression-free survival and overall survival of in patients with metastatic non-squamous NSCLC with no EGFR or ALK mutations.
The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
- In combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full submission
- Not recommended
- Date advice published:
- 11 February 2019